Staphylococcus aureus Thesis (original) (raw)

Antibiotic resistance is a growing problem. New antibiotics have been developed yet shortly after the introduction of these new antibiotics pathogenic bacteria develop resistance to them. The cost involved in the development of novel antibiotics makes it cost prohibitive for most pharmaceutical companies to explore the development of this class of drugs. Small Biotechnology firms have begun to develop biologically active antibodies specific for certain pathogenic bacteria such as Staphylococcus aureus, this approach should stem the tide with regards to the development of antibiotic resistance but ultimately this remains to be seen. Colleges and universities around the world are currently studying the use of biologically active botanical constituents for the treatment of pathogenic infections. Yet the pharmaceutical companies have paid little attention to these studies due in large part to the inability to patent nature.